Early Initiation of DMARD Tx Tied to Greater Reduction in RA Activity
Initiation of DMARD therapy within 6 months of symptom onset was associated with greater reduction in RA disease activity compared with later initiation.
Initiation of DMARD therapy within 6 months of symptom onset was associated with greater reduction in RA disease activity compared with later initiation.
Tofacitinib extended release has comparable clinical efficacy to tofacitinib administered twice daily.
These results challenge existing conceptions that omega-3 fatty acids may be effective in treating adolescent major depressive disorder.